{
    "clinical_study": {
        "@rank": "129481", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A", 
                "arm_group_type": "Experimental", 
                "description": "Cohort A consists of subjects who had completed their treatment with eltrombopag (ELT) during their participation in a parent study for Myelodysplastic syndrome (MDS)/ Acute myeloid leukemia (AML). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 50 to 300 mg once daily (OD) for subjects of non- East Asian heritage. The dose ranges for subjects of East Asian heritage (i.e. Japanese, Chinese, Taiwanese, Thai and Korean) will be 25 to 150 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts."
            }, 
            {
                "arm_group_label": "Cohort B", 
                "arm_group_type": "Experimental", 
                "description": "Cohort B consists of adult subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts."
            }, 
            {
                "arm_group_label": "Cohort C", 
                "arm_group_type": "Experimental", 
                "description": "Cohort C consists of pediatric subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will provide continued access to treatment with eltrombopag for subjects who are\n      currently participating in a GlaxoSmithKline (GSK) sponsored investigational study of\n      eltrombopag (parent study) and to collect long term safety data."
        }, 
        "brief_title": "A Rollover Study to Provide Continued Treatment With Eltrombopag", 
        "completion_date": {
            "#text": "December 2023", 
            "@type": "Anticipated"
        }, 
        "condition": "Thrombocytopaenia", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent has been obtained from the subject (or subject's legally\n             acceptable representative) prior to performance of any study-specific procedure.\n\n          -  The subject is participating in a GSK sponsored investigational study of eltrombopag\n             (parent study) within the past 28 days and is receiving clinical benefit without\n             unacceptable toxicity as determined by the investigator.\n\n          -  Subjects with a QTc <450 millisecond (msec) or <480 msec for subjects with bundle\n             branch block. The QTc is the QT interval corrected for heart rate according to either\n             Bazett's formula (QTcB), Fridericia's formula (QTcF) or another method, machine or\n             manual overread. For subject eligibility and withdrawal QTcF will be used. For\n             purposes of data analysis, QTcF will be used. The QTc should be based on single or\n             averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief\n             recording period.\n\n          -  Women must be either of non-child bearing potential or women with child-bearing\n             potential and men with reproductive potential must be willing to practice acceptable\n             methods of birth control during the study.\n\n          -  Women of childbearing potential must have a negative serum pregnancy test within 14\n             days of the first dose of study treatment and agree to use effective contraception,\n             during the study and for 4 weeks following the last dose of study treatment.\n\n          -  Men with a female partner of childbearing potential must have either had a prior\n             vasectomy or agree to use effective contraception from time of first dose until 16\n             weeks after the last dose of study treatment.\n\n          -  In France, a subject will be eligible for inclusion in this study only if either\n             affiliated to, or a beneficiary of, a social security category.\n\n        Exclusion Criteria:\n\n          -  Permanent discontinuation of eltrombopag in the parent study based upon the study\n             treatment discontinuation or study withdrawal criteria from the parent study.\n             Subjects who permanently discontinued treatment because they completed all study\n             related treatments remain eligible.\n\n          -  The subject is pregnant or a lactating female.\n\n          -  Any serious and/or unstable pre-existing medical, psychiatric disorder or other\n             conditions at the time of transition to this study that could interfere with\n             subject's safety, obtaining informed consent or compliance with the study procedures,\n             in the opinion of the investigator or GSK Medical Monitor.\n\n          -  French subjects: The French subject has participated in any study using an\n             investigational drug during the previous 30 days, with the exception of eltrombopag,\n             in the parent study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957176", 
            "org_study_id": "200170"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort C", 
                "Cohort B", 
                "Cohort A"
            ], 
            "description": "Subjects will be dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets will be white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain ELT olamine equivalent to 20 mg of ELT per gram of powder.", 
            "intervention_name": "ELT", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "myelodysplastic syndromes", 
            "thrombocytopenia", 
            "acute myeloid leukemia", 
            ", idiopathic thrombocytopenic purpura", 
            "Eltrombopag", 
            "pediatrics"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris Cedex 12", 
                        "country": "France", 
                        "zip": "75571"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11527"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Tullamore", 
                        "country": "Ireland"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1081 HV"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France", 
                "Greece", 
                "Ireland", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Europe: European Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2023", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "AEs assessment include: Frequency and severity of AE, AE relationship to IP, AEs leading to permanent discontinuation of study drug, frequency and severity of SAE Laboratory parameters include: hematology and clinical chemistry", 
            "measure": "Safety as assessed by physical examinations, laboratory assessments and monitoring of adverse events or serious adverse events.", 
            "safety_issue": "No", 
            "time_frame": "From the time of the transition visit until 30 days after the last study treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957176"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}